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Epidermal growth factor receptor 1 (EGFR-1) overexpression is usually described as linked with a worse prognosis in a variety of
tumours of epithelial origin. However, its role in ovarian cancer is still controversial. The aim of the present study was to analyse the
prognostic impact of EGFR-1 in a retrospective series of 93 stage III–IV primary ovarian epithelial tumours. All patients, enrolled in a
multicentre GINECO prospective clinical trial, were treated with the same platinum-based combination chemotherapy, and were
followed up with a median of 69 months. Epidermal growth factor receptor 1 plasma membrane expression, assessed by
immunohistochemistry on paraffin-embedded tissues, was correlated with clinical parameters as well as immunohistochemical
expression results of HER-2 (c-erbB-2), BAX, BCL-2, p53 and anti-Ki-67, previously studied in the same series of patients. Positive
immunostaining for EGFR-1 was seen in 31 of the 93 analysed cases (33%). No correlation was found between EGFR-1 expression
and clinical parameters. No correlation was found between EGFR-1 expression and other biological markers, except for HER-2,
which was limit for significance. Indeed, among the EGFR-1-negative cases, 10.3% expressed HER-2, whereas the HER-2-expressing
tumours accounted for 27.6% of EGFR-1-positive cases (P¼0.06). Epidermal growth factor receptor 1 overexpression had no
prognostic impact on both overall and progression-free survival through univariate and multivariate analyses. The potential effect of
EGFR-1 and HER-2 co-expression on targeted therapy against EGFR-1 and/or HER-2 molecules has to be further analysed.
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Ovarian cancer is known to have one of the highest mortality rates
of all gynaecological malignancies. Due to the lack of reliable
tumour markers, most patients present an advanced stage of the
disease at the time of diagnosis. Despite a good initial response to
first-line chemotherapy, prognosis remains poor due in part to the
development of resistance to chemotherapy. According to the
International Federation of Gynecology and Obstetrics (FIGO),
clinical stage, histological grade and postoperative residual tumour
mass are all identified as the most important prognostic factors for
survival in patients with ovarian cancers. Clinical factors as well as
prognostic models derived from these clinical factors (Clark et al,
2001) remain insufficient to predict accurately the outcome for a
specific patient. New markers are needed in order to identify
groups of patients who may benefit from different therapeutic
options. In this paper, we analyse the prognostic role of EGFR-1
immunohistochemical overexpression.
Recently, the interest of the scientific community has increased
for receptors with tyrosine kinase activity, since they constitute
potential therapeutic targets. Among them are HER-2 and EGFR-1,
two of the four known members of the EGFR family. Epidermal
growth factor receptor family receptors (ErbB family) play an
important role in regulating a wide variety of cellular functions,
including regulation of cell cycle, cell death, angiogenesis and cell
differentiation (Alper et al, 2001). After binding the ligand
(epidermal growth factor or transforming growth factor-alpha),
EGFR-1 oligomerises with other EGFR-1 molecules or other
members of EGFR family (e.g. HER-2). Activation of the intrinsic
receptor tyrosine kinase promotes an intracellular pathway,
leading to DNA replication and cell division (Carpenter, 1984).
Abnormal expression of EGFR-1 and its ligands has been shown
in several human cancers, such as lung (Tateishi et al, 1994),
gastric (Yonemura et al, 1992), oral (Storkel et al, 1993; Maurizi
et al, 1996), breast (Hainsworth et al, 1991) and colorectal (Steele
et al, 1990; Kluftinger et al, 1992; De Jong et al, 1998) cancers. The
overexpression of EGFR-1 in ovarian carcinoma and cell lines
derived from this tumour has also been reported. However, the
prognostic impact of EGFR-1 expression in ovarian cancers still
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lremains controversial. In a previous work (Camilleri-Broe ¨t et al,
2003), we showed a poor prognostic impact of HER-2 over-
expression, whereas other tested biological markers (Ki-67, p53,
BCL-2 and BAX) were not of prognostic significance. In the
present study, we analysed EGFR-1 immunohistochemical expres-
sion in a series of homogeneous patients with advanced ovarian
tumours in order to evaluate its prognostic impact.
PATIENTS AND METHODS
Patients
All cases were included in the CEP trial of the GINECO group,
which included from February 1994 through June 1997 164
patients with advanced ovarian cancer (range: 18–70 years). All
patients had a histological proven epithelial ovarian cancer, stage
III or IV according to the FIGO guidelines, a World Health
Organisation (WHO) performance status less than 3, no previous
chemotherapy and no major organ failure. Chemotherapy regimen
consisted of a combination of i.v. cisplatin (75mgm
 2), epirubicin
(50mgm
 2) and cyclophosphamide regimen (CEP) that patients
received for six cycles, with a 21-day interval between each cycle.
The cyclophosphamide regimen was randomised between a
standard dose of 500mgm
 2 and a higher dose of 1800mgm
 2
with G-CSF support. Following the six-cycle chemotherapy course,
patients were regularly monitored at 3 months interval during the
first 3 years and every 6 months thereafter. Second-look
laparotomy was performed in 114 patients (69.5%).
At the time of our analysis, 134 patients (87%) showed a disease
progression, and 117 (71%) deaths have been recorded for the
entire population. The median progression-free survival duration
was 15 months (95% confidence interval (CI): [13.1–16.5]) and the
median overall survival was 32 months (95% CI: [27.7–36.2]).
Response to chemotherapy was evaluated either clinically or with a
second-look laparotomy, defined as a 50% or greater reduction in
the product obtained from the measurement of each lesion and no
appearance of new lesions. Response to chemotherapy was
observed in 74 patients (88%).
There was no statistical difference in response rate, progression-
free survival and overall survival, according to the cyclopho-
sphamide dose in the two treatment arms. For the biological study,
we therefore analysed all patients as a homogeneous population.
Of the 164 patients included in the clinical trial, slides from 93
tumours obtained from first surgery were available for further
immunohistochemical analysis. Clinical and biological variables
were not different when comparing the group to the overall
population (detailed in Table 1). Age was categorised into two
groups: (a) p60 years and (b) 460 years.
Material
For each case, one sample chosen from the first surgery was
reviewed, for histological type and grade, by a panel of pathologists
unaware of the initial diagnosis (for more details, see our previous
work in the same series of patients) (Camilleri-Broe ¨t et al, 2003).
Out of the 93 cases reviewed, 57 cases (61.3%) were diagnosed as
serous or mixed epithelial carcinoma, two (2.2%) were clear cell
carcinoma, seven (7.5%) endometrioid and 26 (28.0%) were
undifferentiated carcinoma. In non-clear cell carcinoma, a clear
cell constituent was found in 10 (10.8%) cases. Among the 93 cases
with primary ovarian tumour samples, nine (9.7%) were con-
sidered as grade 2, 38 (40.9%) cases as grade 3 and 26 (28%) cases
as grade 4 (Table 1).
Immunohistochemistry
Immunohistochemical study was performed with the monoclonal
antibody raised against EGFR-1 (1/10 dilution, NCL-EGFR, clone
EGFR.113; Tebu) on slides obtained from fixed and paraffin-
embedded tissue. Thin 4mm slices were deparaffinised in a routine
manner, followed by a microwave pretreatment in tampon urea
(4 M, pH 7) and 2h incubation with the primary antibody. A
standard streptavidin–biotin–peroxidase method was applied
using a commercially available kit (ABCYS Biospa, Milano),
including 30min incubation for each step, and nuclei were
counterstained with haematoxylin. The immunohistochemical
study was performed in a single laboratory.
All slides were examined by two pathologists without any
knowledge of the clinical data, using a double-headed microscope.
Epidermal growth factor receptor 1-positive expression was
defined as a plasma membrane positivity in more than 10% of
tumour cells. Cytoplasmic staining was considered as nonspecific.
A highly EGFR-1-expressing squamous cell lung carcinoma was
used as a positive control.
Statistical analysis
The relationship between EGFR-1 status and the categori-
cal variables described just below were tested using the w
2
test or Fisher’s exact test, whichever was appropriate: patient
Table 1 Patient characteristics
Clinical trial Biological study
Characteristics N¼164 % N¼93 %
Age
Median 59 60
Range 23–74 23–70
WHO performance status
0 41 25.0 22 23.7
1 98 59.8 56 60.2
2 15 9.1 9 9.7
Missing value 10 6.1 6 6.5
FIGO stage
IIIa 5 3.0 2 2.2
IIIb 30 18.4 16 17.2
IIIc 90 54.9 55 59.1
IV 34 20.7 20 21.5
Missing value 5 3.0 0 0
Ascitis
No 86 52.4 46 49.5
Yes 70 42.7 46 49.5
Missing value 8 4.9 1 1.1
Residual tumour after first laparotomy
No residual disease 20 12.2 11 11.8
Residual disease o2cm 51 31.1 28 30.1
Residual disease 42cm 89 54.3 54 58.1
Missing value 4 2.4 0 0
Histological type
Serous or mixed epithelial 74 45.1 57 61.3
Clear cell 4 2.4 2 2.2
Endometrioid 9 5.5 7 7.5
Undifferentiated 30 18.3 26 28.0
Missing value 47 28.7 1 1.1
Histological grade
Grade 1 0 0 0 0
Grade 2 15 9.1 9 9.7
Grade 3 47 28.7 38 40.9
Grade 4 33 20.1 26 28.0
Missing value 69 42.1 20 21.5
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lcharacteristics (age, WHO performance status, FIGO stage,
residual tumour volume and ascitis), histological subtype, tumour
grade and immunohistochemical results issued from our previous
study (Ki-67, BCL-2, BAX, HER-2 expressions).
Overall survival was calculated from the date of surgery to death
or last follow-up examination. Progression-free survival was
calculated from the date of surgery to progression or last follow-
up examination. Survival curves were derived from Kaplan–Meier
(Kaplan and Meier, 1958) estimates. Univariate Cox model analysis
(Cox, 1972) was performed to estimate and test the prognostic
influence of clinical variables and biological markers/immunohis-
tochemical labelling data. Prognostic impact of EGFR-1 over-
expression, adjusted for the other prognostic factors, was assessed
in multivariate analyses by using the Cox proportional hazards
regression model (Cox, 1972) from a backward stepwise selection
procedure. In this setting, we have selected for the started model
variables associated with prognosis, with a P-value less than or
equal to 0.20 in univariate analyses. Hazard ratios (HRs) associated
with overall survival or progression-free survival are given with
their 95% CI. Statistical significance was considered as P-values
less than 0.05. All these analyses were carried out using the S-Plus
software package.
RESULTS
Expression of EGFR-1 according to clinical and other
biological variables
Epidermal growth factor receptor 1 membrane expression has been
found in more than 10% of tumour cells in 31 out of the 93 cases
tested (33.3%). As we observed previously for HER-2 over-
expression in ovarian carcinomas, some cases showed an
important heterogeneity of expression (Figure 1).
No relationship was found between EGFR-1 expression and all
tested clinical parameters, as well as the previously studied
biological parameters: p53, BAX, BCL-2 and the rate of Ki-67
positivity (Table 2). Among the 87 patients who were tested for
both EGFR-1 and HER-2 expression, eight cases (8.6%) co-
expressed EGFR-1 and HER-2. Among the EGFR-1-negative cases,
six out of 58 (10.3%) expressed HER-2, whereas the HER-2-
expressing tumours accounted for eight of the 29 EGFR-1-positive
cases (27.6%). This link between EGFR-1 and HER-2 over-
expressions was of limited significance (P¼0.06).
Patient’s outcome and response to chemotherapy
Response to chemotherapy was observed in 50 patients of the 59
EGFR-1-negative patients (85%) and in 24 of the 25 EGFR-1-
positive patients (96%). This difference was not significant
(P¼0.27).
At the time of our analysis, out of the 93 patients included in our
retrospective series, 80 patients showed a disease progression
(86.0%) and 74 patients died (79.6%). The median follow-up was
69 months (95% CI: [58.8–79.0]). Within EGFR-1-overexpressing
tumours (31 cases), 28 patients (90.3%) had shown a disease
progression, while 24 (77.4%) died.
In univariate analysis, EGFR-1 expression had no prognostic
impact on progression-free survival (P¼0.80). The median
progression-free survival time was 14.3 months (95% CI: [12.9–
20.2]) in tumours with EGFR-1-negative cases, whereas it was 15.3
months (95% CI: [13.0–27.0]) in EGFR-1-positive cases
(Figure 2A). In contrast, the presence of an ascitis (P¼0.02) and
HER-2 overexpression by tumour cells (P¼0.01) were significantly
associated with shorter progression-free interval.
When focusing on overall survival, EGFR-1 expression still had
no significant prognostic impact (P¼0.45). The median overall
survival duration was 25.6 months (95% CI: [22.6–44.6]) in EGFR-
1 negative cases, whereas it was 34.3 months (95% CI: [29.0–38.9])
in EGFR-1-positive cases (Figure 2B). The presence of an ascitis
(P¼0.03), a high performance status (P¼0.03) and HER-2
overexpression (P¼0.03) were significantly associated with short-
er overall survival.
In the final Cox model for multivariate analysis (Table 3),
presence of ascitis (P¼0.008) and HER-2 overexpression
(P¼0.001) both retained a poor prognostic impact on progres-
sion-free survival. Regarding overall survival, FIGO stage
(P¼0.043), presence of ascitis (P¼0.030) and HER-2 over-
expression (P¼0.008) were linked with a poor overall survival.
When including EGFR-1 expression variable in the previous
multivariate Cox models, it still did not show any prognostic
impact (data not shown).
DISCUSSION
Epidermal growth factor receptor 1 overexpression is thought to be
linked with a poor prognosis in several common solid tumours.
However, regarding ovarian carcinomas, its prognostic value still
remains debated in the literature, showing for some studies a poor
A B
Figure 1 Immunohistochemical labelling results with anti-EGFR-1 antibody-1. (A) Heterogeneous plasma membrane expression for EGFR-1 in tumour
cells. (B) Strong and homogeneous plasma membrane expression for EGFR-1 in tumour cells.
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1997; Skirnisdottir et al, 2001), whereas others showed no
influence of EGFR-1 overexpression on patient’s outcome (Van
der Burg et al, 1993; Meden et al, 1995; Bartlett et al, 1996;
Baekelandt et al, 1999). Only one study in the literature (Bauknecht
et al, 1988) showed a favourable prognostic role of EGFR-1
overexpression, but no multivariate analysis was presented. In this
series, we have found no significant prognostic impact on the
survival time for EGFR-1 overexpression in a homogeneous series
of advanced ovarian cancer patients.
These discrepancies in the prognostic role of EGFR-1 may be
related to different technical methods used, different antibodies
tested, different cutoff values considered, major differences in the
Table 2 Univariate analysis for overall survival and progression-free survival of clinical, histopathological and immunohistochemical parameters
Overall survival Progression free survival
Prognostic factor HR [95% CI] P-values HR [95% CI] P-values
EGFR-1 (% of tumour cells) 0.83 0.45 0.94 0.81
X10% vs o10% [0.51; 1.35] [0.60; 1.50]
Age 1.07 0.76 1.31 0.23
X60 years vs o60 years [0.68; 1.70] [0.84; 2.03]
Performance status 1.95 0.03 1.50 0.15
1/2 vs 0 [1.08:3.52] [0.87; 2.59]
Stage 1.48 0.19 1.10 0.73
IIIc/IV vs IIIa/IIIb [0.83; 2.66] [0.63; 1.91]
Ascitis 1.69 0.03 1.71 0.02
Presence vs absence [1.06; 2.69] [1.09; 2.68]
Residual tumour after first laparotomy 1.15 0.55 1.18 0.46
42 vs o2cm [0.73; 1.83] [0.76; 1.85]
Tumour type 0.81 0.57 1.09 0.79
Clear cell component vs others [0.39; 1.69] [0.58; 2.07]
Tumour grade 0.92 0.75 0.90 0.70
3/4 vs 1/2 [0.54; 1.57] [0.54; 1.52]
Ki-67 expression (% of nuclei surface) 0.96 0.89 0.81 0.41
X30 vs o30 [0.56; 1.65] [0.48; 1.35]
BCL-2 (% of tumour cells) 1.37 0.20 1.19 0.09
X10 vs o10% [0.85; 2.21] [0.94; 2.37]
BAX (% of tumour cells) 0.82 0.41 1.08 0.76
X10 vs o10% [0.51; 1.32] [0.68; 1.71]
p53 (% of tumour cells) 1.11 0.68 1.18 0.49
X10 vs o10% [0.69; 1.79] [0.74; 1.87]
HER-2 (% of tumour cells) 1.99 0.03 2.37 0.01
X10 vs o10% [1.08; 3.69] [1.26; 4.46]
HR¼hazard ratio, CI¼confidence interval.
P-value = 0.802
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Figure 2 Overall survival (A) and progression-free survival (B)
according to EGFR-1 plasma membrane expression.
Table 3 Multivariate analysis for overall survival and progression-free
survival of FIGO stage, ascitis and HER-2 overexpression
Overall survival Progression-free survival
Prognostic factor HR 95% CI P-value HR 95% CI P-value
FIGO stage
IIIa/IIIb 1
IIIc/IIId 2.13 1.02–4.42 0.043 — — —
Ascitis
Absence 1 1
Presence 1.77 1.06–2.97 0.030 1.96 1.20–3.20 0.008
HER-2
o10% of tumour
cells
11 1
X10% of tumour
cells
2.66 1.30–5.44 0.008 3.28 1.61–6.70 0.001
HR¼hazard ratio, CI¼confidence interval.
EGFR-1 immunohistochemical expression and prognosis
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advantage of the immunohistochemical technique is to select
specifically positive plasma membrane expression of receptors by
tumour cells. In contrast, ligand-binding assays give a continuous
result, in part dependent on the proportion of tumour cells present
in the tissue tested, and requires determining a threshold for
positivity.
Four main studies have shown a worse prognosis of the EGFR-1-
positive ovarian carcinomas (Scambia et al, 1992, 1995; Fischer-
colbrie et al, 1997; Skirnisdottir et al, 2001). The first study of
Scambia et al (1992) concerned 72 subjects with stage III and IV
tumours, whereas the second (1995) concerned 117 patients with
all clinical stages. In both studies, the EGFR-1 overexpression
status, assayed by a radioreceptor method, led to a rate of 54%
positive cases. The EGFR-1 overexpression was not linked to
clinical and biological characteristics, but was assessed as an
independent prognosis factor. The study of Fischer-Colbrie et al
(1997) included 108 patients of all clinical stages, with a high rate
of positive patients for EGFR-1 overexpression (61%), determined
with a radioligand-binding assay. The authors found a poor
prognosis impact for EGFR-1 overexpression on progression-free
and overall survival in univariate analysis, but no adjustment on
clinical variables was made, especially as the part of EGFR-1-
positive cases increased significantly with clinical stage in this
study. However, these papers, showing a poor prognostic impact of
EGFR-1 overexpression, had a higher rate of positive cases,
suggesting that the studied positive group may be very different
from that of our series. Moreover, two of them analysed a
heterogeneous series of patients including tumour stages I–IV.
Since EGFR-1 overexpression may increase with the FIGO stage
(Fischer-Colbrie et al, 1997), the exact impact of such correlation
on survival results remains to be investigated. The last study
(Skirnisdottir et al, 2001) included only early stage (FIGO I and II)
epithelial ovarian carcinomas, using thus a population very
different from ours.
Among the main papers which showed no prognostic influence
of EGFR-1 status (Van der Burg et al, 1993; Meden et al, 1995;
Bartlett et al, 1996; Baekelandt et al, 1999), two included a large
number of patients. Baekelandt et al (1999), included 185
homogeneous patients with stage III ovarian cancers. Epidermal
growth factor receptor 1-positive immunostaining, observed in
22% of the cases, had a tendency towards worse prognosis in
univariate analysis, but was not found to be an independent
prognosis factor in multivariate analysis. The study published by
Meden et al included 266 primary ovarian cancer specimens with
FIGO stage I–IV. In all, 13% of the cases were scored positive for
EGFR-1 with an immunohistochemical method, showing no
significant correlation between EGFR-1 status and overall survival.
Our series confirms these findings and is the first study to analyse
a series of homogeneous patients (FIGO stage III–IV), included in
a multicentre clinical trial followed with a long follow-up (median
69 months).
Epidermal growth factor receptor 1 is one of the promising
targets for innovative cancer therapies. Among them, the clinical
interest of inhibitors targeting the tyrosine kinase domains of
EGFR family (Baselga et al, 2002) (e.g. ZD1839, Iressa
s, Astra-
Zeneca) are under clinical investigation. In contrast to HER-2,
whose overexpression predicts clinical response to trastuzumab
(Herceptin
s), it seems that EGFR-1 overexpression is not
necessary for using the therapies targeting its activity (Arteaga,
2002). Indeed, in addition to high expression of the receptor,
EGFR-1 signalling may be upregulated by increased expression of
its ligands, activating receptor mutations, heterodimerisation with
other members of the family such as HER-2, and alterations of
downstream molecules in the signalling pathway. Only assessment
of these different steps may provide a more complete information
on the activation of the EGFR pathway and thus on potential
response to EGFR-targeted agents.
Some papers suggest that EGFR-1 overexpression could
potentialise the antineoplastic activity of other classical drugs of
chemotherapy or ionising radiation in vitro or in vivo in nude mice
(Ciardiello et al, 1999; Bianco et al, 2002; Kari et al, 2003). The
principle of such cooperation seems to induce apoptosis, following
a downregulation of the antiapoptotic BCL-2 and BCL-XL proteins.
In our study, we have found no correlation between BCL-2 and
EGFR-1 expressions. In a clinical setting, conflicting results have
been reported with regard to response to chemotherapy and EGFR-
1 overexpression. In contrast to Scambia et al. (1995), who found
that EGFR-1 overexpression was of borderline significance in
response to chemotherapy, we did not observe such a correlation
in our series, similar to that observed by other papers (Baekelandt
et al, 1999; Ferrandina et al, 2002). However, further studies are
needed to analyse its potential impact on patients treated with
other regimens, including paclitaxel.
In our series, a positive correlation of limited significance
(P¼0.06) was found between EGFR-1 and HER-2 overexpressions,
similar to that found by Ferrandina et al. (2002) and Skirnisdottir
et al. (2001). Heterodimerisation of EGFR-1 and HER-2 is
functionally active. We have not observed prognostic impact for
EGFR-1 and HER-2 co-expressing tumours as compared to the
HER-2-positive/EGFR-1-negative group, but this comparison was
made with a limited number of patients (data not shown). A recent
study from Christensen et al. (2001) showed in vitro and in vivo in
nude mice that it is more difficult to inhibit EGFR-1 phosphoryla-
tion in cells that express high levels of HER-2 expression. However,
in clinical practice, no relationship between HER-2 overexpression
and response to ZD1839 (Iressa
s) was shown in a series of
patients suffering from non-small-cell lung cancer (Cappuzzo et al,
2003). Further studies are needed to answer this question in
ovarian carcinomas.
In conclusion, our study showed the lack of prognostic impact
of EGFR-1 overexpression in a large homogeneous population of
stage III and IV ovarian cancer, included in a multicentre clinical
trial. However, the absence of prognostic impact eliminates neither
a possible role of EGFR-1 in oncogenesis nor a potential benefit of
EGFR-targeted agent. Moreover, since a positive correlation of
limited significance between EGFR-1 and HER-2 expressions was
found, further studies are needed to investigate the clinical effect of
such co-expression in a population treated by other regimens,
including paclitaxel or targeted therapies.
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